精神病学合作伙伴关係和许可协议（2019-2024）

Psychiatry Collaboration and Licensing Deals 2019-2024

出版日期: 2024年10月01日 | 出版商:

Current Partnering | 英文 300+ Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

本报告审查了 2016 年至 2024 年期间与精神病学相关的 541 份合作伙伴关係和许可协议，并审查了交易总数、财务交易状况以及交易活跃度最高的 25 家公司的趋势。、合约文件等

主要优点

该报告为读者提供了以下主要好处：

了解 2016 年以来的合约趋势
查看业务伙伴交易
基准分析：确定交易的市场价值
财务状况
交易清单：按公司名称 (A-Z)、治疗领域和技术类型
主要交易（金额基础）
最活跃的谈判者
每笔交易的资产识别和交易条件
取得合约文件：深入了解交易结构
尽职调查：评估拟议交易条款对合作伙伴公司的适用性
节省数百小时的研究时间

合约分析允许尽职调查：

授予/选择了哪些权利？
合约授予了哪些权利？
授予哪些类型的专有权？
合约的付款结构为
如何审核销售和付款？
合约期限为
合约的主要条款是如何定义的？
如何对待和拥有知识产权？
谁负责商业化？
谁负责开发、供应和製造？
如何管理保密和发布？
如何解决争议？
什么情况下可以取消合约？
如果所有者发生变化会怎样？
已就哪些从属许可或分包条款达成协议？
公司需要哪些样板条款？
哪些样板条款看起来有所不同，取决于合作伙伴和交易类型？
每家公司对契约法主张哪一个管辖权？

精神科领域的交易：依治疗目标分类
交易目录
交易目录：依公司划分（2016-2024 年）
贸易名录：依技术类型分类（2016-2024 年）
交易类型的定义
关于生物製药研究股份有限公司
目前的合作关係
当前合约
Current Partnering 最近的报告标题

简介目录

Product Code: CP2204

Psychiatry Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the psychiatry deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of 541 psychiatry deals from 2019 to 2024.

The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of collaboration and licensing deals announced since 2019 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of psychiatry dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in psychiatry dealmaking.

Chapter 3 covers the financial deal terms for deals signed in the psychiatry field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.

Chapter 4 provides a review of the top 25 most active biopharma companies in psychiatry dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive and detailed review of psychiatry deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of psychiatry deals listed by theraeutic target.

The report also includes numerous table and figures that illustrate the trends and activities in psychiatry deal making since 2019.

In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Psychiatry Collaboration and Licensing Deals provides the reader with the following key benefits:

Understand deal trends since 2019
Browse psychiatry collaboration and licensing deals
Benchmark analysis - identify market value of transactions
Financials terms - upfront, milestone, royalties
Directory of deals by company A-Z, therapy focus and technology type
Leading deals by value
Most active dealmakers
Identify assets and deal terms for each transaction
Access contract documents - insights into deal structures
Due diligence - assess suitability of your proposed deal terms for partner companies
Save hundreds of hours of research time

Report scope

Psychiatry Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of psychiatry trends and structure of deals entered into by leading biopharma companies worldwide.

Psychiatry Collaboration and Licensing Deals includes:

Trends in psychiatry dealmaking in the biopharma industry
Overview of collaboration and licensing deal structure
Directory of psychiatry deal records covering pharmaceutical and biotechnology
The leading psychiatry deals by value
Most active psychiatry licensing dealmakers

In Psychiatry Collaboration and Licensing Deals, the available deals are listed by:

Company A-Z
Headline value
Therapeutic area
Technology type
Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
Psychiatry Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?